Lynparza – Talk Bio

Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

5 months ago talkbio0Tagged Clinical Trials, Keytruda, Lynparza, ovarian neoplasm, Progression-Free Survival, Survival

Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

8 months ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

AstraZeneca’s Lynparza Demonstrates Nearly 50% Response in Advanced Breast Cancer Patients: #AACR24 Update

1 year ago talkbio0Tagged 50, AACR24, advanced breast cancer, AstraZeneca, Frequency of Responses, Inhibitor, Lynparza, olaparib, PARP1 gene

AstraZeneca, Lynparza (olaparib), PARP inhibitor, Advanced breast cancer, 50% response rate, AACR24